The World Orphan Drug Congress USA unfolds today at the Boston Convention and Exhibition. With over 2,400 participants coming together, the main theme of “Breaking down silos and fostering collaboration to help rare disease patients” sets the stage for impactful discussions.

The conference will talk about various interesting topics including advanced therapies in commercialization and clinical development, as well as diagnosis and discovery with the use of AI and machine learning.

Among the key highlights are:
🌟 Patient Data: With the significance of real-world data (RWD/RWE) in rare disease management.
🌟 Rare Oncology: Precision diagnosis is revolutionizing the rare cancer landscape, emphasizing the necessity for collaboration among stakeholders.
🌟 Commercial Strategies: Exploring effective commercial approaches for orphan products is imperative.
🌟 Rare Disease Advocacy: Advocacy efforts, centered around patients, are paramount. Understanding the challenges faced by rare disease patients and organizations is key.
🌟Digital Health & Artificial Intelligence: Approaches in AI and digital health span the full development life cycle of drug development and commercialization.

The WODC24 brings together leading pharmaceutical and biotech companies, government and regulatory authorities, patient advocacy groups, payers, investors, and solution providers. The conference is a place to meet and brainstorm ways to advance orphan drug development and improve access to life-saving therapies.

WODC aligns with Clinakos Inc. dedication to advancing rare disease research and improving patient outcomes. Our focus on PatientData and Medically Smart AI drives our mission.